Innovative drug overseas Xinhengrui sells PD-1 monoclonal antibody to Incyte for US$795 million

September 7, 2015 - Incyte announced that it has obtained the overseas exclusive R & D and sales right of Jiangsu Hengrui pharmaceutical PD-1 monoclonal antibody shr-1210, which is still in the research stage for advanced solid tumor patients Incyte said in the agreement that the deal will bring at least $795 million in revenue to Hengrui pharmaceutical, including some unspecified parts Shr-1210 is a kind of immunocheckpoint blocker, which is used to inhibit the interaction between PD-1 and PD-L1 Shr-1210 will be evaluated in a non blinded, multicenter, non randomized phase 1 clinical trial in which patients have not been recruited as of July 6 The upcoming clinical trials will recruit a group of patients with advanced solid tumors who have no effect on the existing anti-tumor treatment, and the whole phase 1 clinical trial is expected to be completed in July 2016 HERV é hoppenot, chairman and CEO of Incyte, said that the addition of shr-1210 has injected new vitality into the company's efforts to strengthen the diversification of tumor drug research and clinical research and development After the down payment of US $2500 from Hengrui pharmaceutical, Incyte will obtain exclusive R & D and sales rights except for mainland China, Hong Kong, Macao and Taiwan In addition, Incyte promised to pay Hengrui $770 million in milestone payments Incyte said the milestones included $90 million of approved milestones, $530 million of sales milestones and $150 million of Clinical Excellence milestones In addition, after the overseas listing of shr-1210, Hengrui will also make a percentage of Incyte's sales Incyte said that both parties will assume financial responsibility for research and development and sales of shr-1210 in their respective regions Sun piaoyang, chairman of Hengrui, said that the cooperation between the two sides can integrate their resources and accelerate the R & D of shr-1210 Hengrui is very happy to cooperate with Incyte Jiangsu Hengrui Pharmaceutical Co., Ltd was founded in 1970, with its headquarters in Lianyungang, Jiangsu Province The annual sales volume of Hengrui pharmaceutical is more than 1.2 billion US dollars In addition to the tumor business, Hengrui is also committed to the fields of Hematology, anesthesia, pain, cardiovascular, metabolism, angiography and inflammation Source: Incyte to co develop Hengrui's shr-1210 in up to - $795m deal